TMEM229A Inhibitors
TMEM229A inhibitors pertain to a class of chemical compounds designed to specifically bind to and inhibit the function of the protein TMEM229A. TMEM229A, short for Transmembrane Protein 229A, is a protein that, as its name suggests, spans the membrane of cells. Proteins that reside in cell membranes play critical roles in various cellular processes including signaling, transport, and cellular integrity. Inhibitors targeting TMEM229A are crafted through a process of molecular design, which involves understanding the structure and function of the protein at a detailed level. This enables chemists to create molecules that can interact with the protein in a highly specific manner, blocking its normal function.
The development of TMEM229A inhibitors requires a deep understanding of biochemistry and molecular biology. Researchers must first elucidate the structure of TMEM229A, which is often achieved through techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. Knowing the structure allows scientists to identify potential binding sites where an inhibitor could effectively attach without affecting other proteins. This specificity is crucial to ensure that the inhibitors do not inadvertently interact with other proteins and cause off-target effects. Once potential binding sites are identified, chemical synthesis and iterative design are employed to create molecules that fit these sites. These molecules are then tested in various assays to confirm their inhibitory activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. It can indirectly inhibit TMEM229A by disrupting the PI3K/Akt signaling pathway, which may play a role in the trafficking and function of transmembrane proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that can lead to the indirect inhibition of TMEM229A by blocking the PI3K/Akt pathway, affecting the cellular processes that involve transmembrane proteins. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can indirectly affect TMEM229A by inhibiting the mTOR signaling pathway, which intersects with various transmembrane protein functions including sorting and signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that potentially influences TMEM229A activity by inhibiting p38 MAPK-dependent signaling pathways, which could affect the sorting or signaling roles of TMEM229A. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that may indirectly inhibit TMEM229A by blocking the MEK/ERK pathway, which is involved in the regulation of various transmembrane proteins. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which could impact TMEM229A function by modulating the ERK/MAPK signaling pathway, possibly affecting transmembrane protein-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can indirectly lead to the inhibition of TMEM229A by blocking JNK signaling, which may influence the behavior of transmembrane proteins in cells. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function, which could indirectly inhibit TMEM229A by impairing the proper trafficking and maturation of transmembrane proteins. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which could indirectly lead to TMEM229A inhibition by affecting the folding and stability of glycosylated transmembrane proteins. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts lysosomal acidification, which can indirectly inhibit TMEM229A by interfering with the degradation or recycling pathways of transmembrane proteins. | ||||||